Low Levels of Klothos Linked to Kidney Function Decline
|
By LabMedica International staff writers Posted on 15 Feb 2017 |

Image: The Dade Behring BN II automated nephelometer system (Photo courtesy of Siemens Healthcare).
The kidney has the highest levels of klotho expression and is likely the major source of soluble klotho and not surprisingly, therefore, levels of klotho tend to be low in patients with kidney disease.
Soluble klotho is a protein circulating in the blood that is thought to have anti-aging properties and although the exact mechanism of action of soluble klotho remains to be identified, the protein has been shown to influence multiple cellular and endocrine pathways.
A large team of scientists led by those at Tufts Medical Center carried out a prospective cohort initiated in 1997 with a goal of assessing how health conditions affect age-related physiologic and functional status. The study population consists of 3,075 persons aged 70 to 79 years at baseline with equal numbers of men and women and approximately one third African-Americans. All 2,496 participants who had measures of klotho and kidney function at baseline, and at least one repeat measure of kidney function were included in this study.
Serum soluble α-klotho was assayed using a commercially available sandwich enzyme-linked immunosorbent assay (ELISA) test from never-thawed frozen serum stored at -70 °C and obtained at the year two visit, approximately one year after the baseline visit. This assay is reported to have a sensitivity of 6.15 pg/mL, and demonstrated an interassay coefficient of 18%. The associations between soluble klotho levels and decline in kidney function and incident chronic kidney disease (CKD) were evaluated. Cystatin C was measured at baseline, as well as years three and 10, from stored frozen serum samples using a BNII nephelometer and an N Latex Cystatin C particle-enhanced immunonephelometric assay.
The scientists found that the median (25th, 75th percentiles) klotho level was 630 (477, 817) pg/mL. In fully adjusted models, each two-fold higher level of klotho associated with lower odds of decline in kidney function (odds ratio, 0.78) for 30% decline in estimated glomerular filtration rate (eGFR), and 0.85 for greater than 3 mL/min per year decline in eGFR, but not of incident CKD (incident rate ratio, 0.90). Overall, a higher soluble klotho level independently associated with a lower risk of decline in kidney function.
David A. Drew, MD, MS, the lead author of the study, said, “We found a strong association between low soluble klotho and decline in kidney function, independent of many known risk factors for kidney function decline. This suggests that klotho could play a role in the development of chronic kidney disease, although additional studies will need to confirm this. This also raises the possibility that klotho could be an important therapeutic target for future clinical trials.” The study was published on January 19, 2017, in the Journal of the American Society of Nephrology.
Soluble klotho is a protein circulating in the blood that is thought to have anti-aging properties and although the exact mechanism of action of soluble klotho remains to be identified, the protein has been shown to influence multiple cellular and endocrine pathways.
A large team of scientists led by those at Tufts Medical Center carried out a prospective cohort initiated in 1997 with a goal of assessing how health conditions affect age-related physiologic and functional status. The study population consists of 3,075 persons aged 70 to 79 years at baseline with equal numbers of men and women and approximately one third African-Americans. All 2,496 participants who had measures of klotho and kidney function at baseline, and at least one repeat measure of kidney function were included in this study.
Serum soluble α-klotho was assayed using a commercially available sandwich enzyme-linked immunosorbent assay (ELISA) test from never-thawed frozen serum stored at -70 °C and obtained at the year two visit, approximately one year after the baseline visit. This assay is reported to have a sensitivity of 6.15 pg/mL, and demonstrated an interassay coefficient of 18%. The associations between soluble klotho levels and decline in kidney function and incident chronic kidney disease (CKD) were evaluated. Cystatin C was measured at baseline, as well as years three and 10, from stored frozen serum samples using a BNII nephelometer and an N Latex Cystatin C particle-enhanced immunonephelometric assay.
The scientists found that the median (25th, 75th percentiles) klotho level was 630 (477, 817) pg/mL. In fully adjusted models, each two-fold higher level of klotho associated with lower odds of decline in kidney function (odds ratio, 0.78) for 30% decline in estimated glomerular filtration rate (eGFR), and 0.85 for greater than 3 mL/min per year decline in eGFR, but not of incident CKD (incident rate ratio, 0.90). Overall, a higher soluble klotho level independently associated with a lower risk of decline in kidney function.
David A. Drew, MD, MS, the lead author of the study, said, “We found a strong association between low soluble klotho and decline in kidney function, independent of many known risk factors for kidney function decline. This suggests that klotho could play a role in the development of chronic kidney disease, although additional studies will need to confirm this. This also raises the possibility that klotho could be an important therapeutic target for future clinical trials.” The study was published on January 19, 2017, in the Journal of the American Society of Nephrology.
Latest Clinical Chem. News
- FDA-Approved Test Identifies Low Risk of Large Esophageal Varices in Cirrhosis
- Blood Protein Signature Diagnoses Pediatric IBD and Distinguishes Subtypes
- Blood Test Detects More High-Risk Prostate Cancers Than PSA
- Rapid Blood Test Aids Diagnosis of Acute Ischemic Stroke
- Blood-Based Alzheimer’s Testing Platform Offers Rapid Results
- Maternal Blood Biomarkers Identify Risk of Preterm and Early-Term Birth
- Simple Oral Swab Monitors Persistent Inflammation in Primary Ciliary Dyskinesia
- Simple Blood-Based Cholesterol Efflux Assay Identifies High-Risk Coronary Plaque Features
- Plasma Vitamin C Levels Associated with Brain Structure and Connectivity in Aging
- Mass Spectrometry Detects Tumor Metabolites for Cancer Monitoring
- Urinary Biomarker Assay Predicts Kidney Disease Progression Beyond Standard Measures
- Saliva-Based Test Detects Biochemical Signs of Sleep Loss
- Simple Dual-Tau Blood Test Detects and Stages Alzheimer’s Disease
- Alzheimer’s Blood Biomarkers Linked to Early Cognitive Differences Before Dementia
- Urine-Based Test Shows Promise for Autism Screening in Children
- Blood-Based Sensor Detects Early Signs of Alzheimer’s and Parkinson’s
Channels
Molecular Diagnostics
view channel
New Molecular Marker Helps Predict Multiple Myeloma Prognosis
Multiple myeloma is a bone marrow cancer marked by resistance to therapy and frequent relapse, complicating long-term disease control. Better molecular markers are needed to refine risk assessment and... Read more
Blood-Based RNA Biomarker Improves Prediction of Alzheimer’s Onset
Timely identification of patients approaching symptomatic Alzheimer’s disease (AD) remains a major clinical challenge, even as blood-based biomarkers continue to advance. Current assays are highly effective... Read moreHematology
view channel
Next-Generation Hematology Platform Streamlines High-Complexity Lab Workflows
Sysmex America (Chicago, IL, USA) has introduced the next generation XR-Series, centered on the XR-10 Automated Hematology Module for high-complexity laboratories. The platform builds on the widely used... Read more
Blood Eosinophil Count May Predict Cancer Immunotherapy Response and Toxicity
Immune checkpoint inhibitors have improved outcomes across many cancers, yet only a subset of patients derive durable benefit and biomarkers to guide treatment remain limited. Eosinophils, best known for... Read moreImmunology
view channel
Anti-Lipid Antibody Biomarkers May Identify Early Lyme Disease and Persistent Symptoms
Lyme disease is often missed during its earliest and most treatable stage, while current serologic assays cannot distinguish active infection from prior exposure. Nearly half a million Americans are diagnosed... Read more
Emergency Department Opt-Out Testing Program Identifies Undiagnosed HIV
Undiagnosed HIV continues to drive avoidable morbidity and transmission, with many people identified only after substantial immune damage has occurred. In England, about one in 20 people living with HIV... Read more
Immune Biomarkers Could Identify Risk of Chronic Critical Illness on ICU Admission
Severe traumatic injury can trigger immune and organ dysfunction that complicates recovery in the intensive care unit. A subset of patients develop chronic critical illness, defined as dependence on intensive... Read moreMicrobiology
view channel
Rapid Gastrointestinal PCR Panels Deliver One-Hour Results
Acute infectious gastroenteritis remains a major cause of illness worldwide, especially in young children, older adults, and immunocompromised patients. Nonspecific symptoms such as diarrhea, vomiting,... Read more
H. pylori Screening Within Colorectal Program Aids Gastric Cancer Prevention
Health systems increasingly rely on economic evidence to guide cancer prevention strategies. For gastric cancer, selecting screening approaches that can integrate with existing programs is a key policy question.... Read more
Machine Learning Reveals Consistent Gut Microbiome Patterns in Colorectal Cancer
Colorectal cancer has been repeatedly linked to alterations in the gut microbiome, yet findings have often varied across small, heterogeneous studies. Reproducibility has been limited by differing sequencing... Read morePathology
view channel
AI Pathology Tool Predicts Immunotherapy Response in Rare Cancers
Immunotherapy has transformed care for select malignancies, yet predicting which patients with rare cancers are most likely to benefit remains challenging. Clinicians often have only limited biomarkers... Read more
Uncertainty-Aware AI Tool Improves Digital Pathology for Cancer Subtyping
Reliable histologic subtyping guides therapy selection in oncology, yet diagnostic workflows grow more complex as whole-slide imaging and artificial intelligence (AI) expand. A persistent obstacle to clinical... Read moreTechnology
view channel
AI Platform Links Biomarker Results to Cancer Clinical Trials and Guidelines
Oncology teams must manage growing volumes of genomic data, rapidly evolving clinical trial options, and frequently updated care guidelines, all within tight clinic schedules. Translating complex tumor... Read more
Agentic AI Platform Supports Genomic Decision-Making in Oncology
Oncology care teams increasingly face the challenge of managing complex molecular diagnostics, evolving treatment options, and extensive electronic health record documentation. Translating multimodal data... Read moreIndustry
view channel
Partnership Integrates Automated DNA Extraction with Single-Molecule Digital PCR
Countable Labs (Palo Alto, CA, USA) and Promega (Madison, WI, USA) have entered a co-marketing agreement that integrates the Promega Maxwell System for nucleic acid extraction with Countable Labs’ Countable... Read more








